Syndax's Revumenib Achieves 82% ORR, 97% CRc in AML Clinical Trials
Summary
Syndax Pharmaceuticals announced impressive clinical trial data for its menin inhibitor, revumenib, showing an 82% Overall Response Rate (ORR) and 64% Complete Remission/Complete Remission with partial hematologic recovery (CR/CRh) in relapsed/refractory NPM1/KMT2A AML patients. In combination therapy, revumenib achieved a 97% Complete Remission with count recovery (CRc) and 86% MRD negativity in Phase 1. These highly positive efficacy results are critical for Syndax's pipeline, indicating significant potential for revumenib in a challenging cancer population. This clinical update follows the company's recent $250 million convertible senior notes offering and strong Q1 financial results. Further data from the ongoing EVOLVE-2 and RAVEN trials will be important to watch.
At the time of this announcement, SNDX was trading at $17.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $8.59 to $25.59. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.